Bioterrorism Antitrust Relief Is One Of Last Major Obstacles To Consensus Bill
Executive Summary
Antitrust exemptions for pharmaceutical companies who produce bioterrorism countermeasures is one of the last significant obstacles to moving an anti-bioterrorism authorization bill this year